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Abstract
Liver transplantation is the treatment of choice for end stage liver disease and is often used for primary liver malignancies.
The main limitation of its wider application is the availability of suitable donor organs. The use of marginal donor organs,
split-liver transplantation and living-related liver transplantation techniques contribute to increase the donor pool.
However, the use of these techniques is associated with a higher risk of post transplantation organ dysfunction,
predominantly due to ischaemia, preservation and reperfusion injury (IPRI). A number of studies have demonstrated that
hyperbaric oxygen (HBO) therapy influences IPRI and consequential acute cellular rejection. This article reviews the
rationale of HBO therapy in the field of transplantation with particular emphasis on liver transplantation.
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Introduction
Liver transplantation is an established therapeutic
modality for acute and chronic liver diseases. The
improvement in outcome of liver transplantation is
related to advances in patient selection criteria, organ
preservation, operative techniques, perioperative care
and efficacy of immunosuppressive agents. The re-
sultant increase in demand for donor organs, widely
estimated to be between 15 and 80 per million
population, has led to the development of many
strategies [1]. These include the use of split-liver
transplantation [2,3], living-related transplantation
[4,5], domino transplantation [6], non-heart beating
donor transplantation and the use of marginal donor
organs. These techniques result in the procurement of
an organ that potentially has suboptimal function
compared with normal organs, either due to the
reduction in mass or the functional quality of the
tissue [7]. Such organs are more susceptible to
ischaemia, preservation and reperfusion injury
(IPRI), which accounts for the majority of graft loss.
A further cause for donor organ damage is
acute cellular rejection (ACR), which affects approxi-
mately 3040% of patients after transplantation.
Although ACR is effectively treated with modern
immunosuppressive agents, this adds significantly to
the postoperative morbidity and overall cost of
transplantation. Recent evidence suggests a correla-
tion between the severity of IPRI and ACR. Limiting
the severity of IPRI may reduce the incidence of
primary non-function (PNF) as well as ACR after
liver transplantation. Hyperbaric oxygen (HBO) ther-
apy has been shown to reduce the severity of IPRI as
well as modulate both humoral and cellular immune
response. This paper provides an overview of the
relationship between IPRI and ACR and the potential
therapeutic implications of HBO therapy in liver
transplantation.
Pathophysiology of the interaction of IPRI and
ACR
The cumulative effect of warm ischaemia and cold
preservation is an energy deficiency within the Kupf-
fer and endothelial cells leading to intracellular
oedema [8]. The early stages of reperfusion are
characterized by a depletion of L-arginine, a precursor
of the potent vasodilator nitric oxide (NO) and an
elevation of endothlin-1 (ET-1). The latter stimulates
hepatic stellate cell contraction, leading to sinusoidal
narrowing, congestion and impaired flow. The low
velocity within the sinusoids progressively promotes
leucostasis, further hindering sinusoidal blood flow
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and exacerbating the hypoxic injury to the donor
organ [9]. Activation of Kupffer cells follows with the
release of potent inflammatory cytokines such as
tumour necrosis factor (TNF)-a and interleukin-1
(IL-1) as well as the production of reactive oxygen
species (ROS) [10]. The proinflammatory activity of
these cytokines manifests through many pathways,
including the increased expression of adhesion mole-
cules. These further increase the leukocyteendothe-
lial cell interactions and the induction of IL-8
synthesis [1114].
An additional effect of IPRI is its potential to
stimulate host response in the form of acute cellular
rejection. Many antigens that are not normally present
on vascular endothelium and biliary epithelium are
expressed in response to IPRI. This exposure results
in an innate immune response that involves humoral
components such as cytokines, complement and
coagulation proteases as well as cellular components
made up of macrophages and neutrophils. This initial
response is followed by an adaptive immune response
which leads to the activation of T and B cells acting
specifically against exposed allo-antigens. Apart
from antigen exposure, IPRI-induced tissue injury
also results in the increased expression of adhesion
molecules. These include P and E selectins as well
as vascular cell adhesion molecule (VCAM). Chemo-
kines such as macrophage chemoattractant protein
1 (MCP-1) and IL-8 lead to the mobilization of
macrophages and neutrophils towards the injured
tissue. Integrins are then expressed allowing leuko-
cytes to adhere and transmigrate to the target tissues.
IPRI also leads to the activation of the complement
system by both the classical and alternate pathways.
Activation of the latter pathway leads to the release
of further IL-8 and platelet activating factors (PAFs),
which aggravates the inflammatory response at the
site of injury.
Accumulating evidence indicates an association
between IPRI and the onset and severity of acute
rejection. The significance of the innate immune
response and its relationship to the adaptive immune
response has become clearer. The initial signal
activation for the innate response is mainly provided
through dendritic cells. A number of stress proteins
that are expressed as danger signals, namely the heat
shock protein family (HSP), act as endogenous
ligands to Toll-like receptors (TLRs) [15]. Extracel-
lular release of HSPs resulting from cell injury is thus
able to act through TLRs to induce activation and
maturation of antigen-presenting cells (APCs), parti-
cularly dendritic cells [16,17].Other studies have not
only confirmed the role of ROS in inducing the
endogenous ligands of TLRs but also the central
role played by TLR4 to establish the full impact of
hepatic IPRI [18].
Tissue injury that follows due to IPRI leads to
activation of donor APCs within the graft and
recipient APCs that enter the graft. Activated APCs
then migrate to secondary lymphoid tissue where they
interact with T cells and induce the allo response.
Activation of APCs by TLRs also overcomes
the suppression of T helper cells by CD4 CD25
T cells, allowing progression of the adaptive response
[19]. It may be hypothesized that reducing IPRI and
minimizing the activation of TLRs may leave the
APCs in an inactivated state, leading to antigen-
specific tolerance [20]. Absence of previous evidence
supporting the relationship between IPRI and the
severity of allo rejection have been attributed to the
use of potent immunosuppressive agents [21]. More
recent clinical studies have shown a closer association
of IPRI and ACR [22] and the important role played
by the innate response [23,24].
The pathophysiology underlying acute cellular
rejection is complex, multi-factorial and not fully
understood. The host response to donor allo-antigens
is centred on the major histocompatibility complex
(MHC) antigens, while donor dendritic cells within
the organ are thought to exert the most potent
stimulus for the onset of acute rejection [2527].
Antigen recognition may occur by direct or indirect
allo-recognition. Antigen specificity is maintained by
T-cell receptor (TCR) complex while CD4 and CD8
act as co-receptors, binding to class II and class
I MHC antigens, respectively. Once the TCR is
engaged to an allo-antigen a series of intracellular
events leads to the production of IL-2 [2830].
Maximal IL-2 production by activated T cells is
dependent on co-stimulation through a number of
molecules, the most important of which seems to be
CD28. The majority of CD4 T cells and approxi-
mately 50% of CD8 T cells express CD28 on their
surface, the absence of which fails to induce an
immune response from such T cells [31].
Activation of IL-2 and IL-2 receptors is followed by
IL-3, IL-4, IL-5, IL-6 and interferon-g. These activ-
ities lead to the transformation of the T cells to take
on differentiated functions, such as immunoregula-
tion and cytotoxicity. The exact roles of various
cytokines remain unclear, although there is cross-
regulation between the two types of CD4 cells and
some cytokines have been shown to have both
immunostimulatory and immunomodulatory effects.
Activated CD8 T cells achieve destruction of target
cells by the secretion of perforins and granzymes.
Perforins create large pores in the target cell mem-
brane leading to cytolysis, while granzymes activate
apoptosis in the target population [32].
Mechanisms of the immunomodulatory effects
of hyperbaric oxygen
The focus of HBO therapy has been directed towards
its effect on IPRI. Researchers have also identified a
significant immunomodulatory effect in animal stu-
dies by treating grafts in culture [33] as well as the
recipients [34,35]. These studies have demonstrated a
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suppressive effect on both humoral [36] and cell-
mediated immunity [35]. As the mechanisms of
allograft rejection became better understood, the
potential mechanisms of action of HBO were further
investigated. Most of these studies were aimed at
understanding the effects of HBO on the release of
cytokines and modulation of leukocyte function and
have been conducted via in vitro or in vivo studies in
normal human volunteers.
The effect of both HBO and its components
(normobaric hyperoxia and hyperbaric normoxaemia)
on the release of TNF-a has been studied in detail
[37]. In vitro studies have shown that the release of
TNF-a from unstimulated macrophages requires both
the hyerbaric and hyperoxaemic components. In
contrast, macrophages exposed to bacterial lipopoly-
saccharide (LPS) only require the hyperbaric compo-
nent. Some investigators demonstrated an initial
increase in TNF-a and IL-1 secretion in patients
with Crohn’s disease [38] and normal volunteers [39]
during HBO therapy but a subsequent reduction with
prolonged HBO therapy. Whether prolonged expo-
sure to HBO inhibits production or if it was due to
initial depletion of these cytokines is uncertain [38].
The study of IFN-g in human volunteers also further
supports the immunomodulatory effect of HBO
therapy. Production of IFN-g by peripheral blood
lymphocytes was significantly inhibited for 24 h
following exposure to HBO therapy. Further studies
have demonstrated this effect to be attributed pre-
dominantly to the hyperbaric effect rather than to
hyperoxaemia [40]. Animal studies have further
supported the depressive effect on IFN-g by hyper-
baric therapy in the absence of hyperoxaemia [41].
This has led to the conclusion that the hyperbaric
effect acts on the cellular cytoskeleton, leading to a
reduction in IFN-g rather than the increase in oxygen
tension.
Early studies reporting an immunosuppressive ef-
fect from HBO therapy implicated a defect in the
macrophagemonocyte system [34,42]. Recent stu-
dies investigating leukocyte function in response to
HBO therapy have focused mainly on in vitro func-
tions of neutrophils (PMNs) and lymphocytes. PMN
function, particularly bactericidal ability, is related to
the oxygen tension of its environment [43]. HBO
therapy was shown to not impede the ability of PMNs
to phagocytose or develop the oxidative burst by
Gadd et al., demonstrating that PMN phagocytosis
was possibly independent of the oxygen tension [44].
PMNs have the ability to inhibit T-lymphocyte func-
tion in their vicinity due to the release of myeloper-
oxidase and H2O2 [4547]. This appears to be one
of the mechanisms by which immunomodulation
of T cells seem to occur after HBO therapy, as
demonstrated by Gadd et al. where inhibition of
T-lymphocyte proliferation was noted in response to
HBO therapy. Despite this finding, there appear to be
subpopulations of T lymphocytes that are resistant to
the inhibitory effects of PMN-induced H2O2 [46].
An in vitro study by MacKenzie et al. demonstrated
the failure of peripheral blood monocytes treated with
HBO therapy to activate lymphocytes when exposed
to allogenic stimuli [48]. In this study the investigators
elegantly demonstrated the inhibition of cytotoxic
T lymphocyte activation by HBO therapy. The main
focus was shown to be due to its effect on CD4 cells.
The addition of the T helper 1 cytokine IFN-g to the
culture reversed this effect. The administration of
anti-IL-4 and anti-IL-10 blocking antibodies which
are T helper 2-related cytokines also restored nor-
malcy to the T lymphocytes. However, when the
CD4 cells were removed prior to re-stimulation, the
CTL activity was restored. Interestingly, the addition
of IL-2 to cells treated by HBO did not stimulate
CTL activity, suggesting that the mechanism of HBO
immunomodulation was other than the creation of
anergy. It is more likely, based on the above results,
that HBO therapy acts by modulating the CD4 cells
which cross-regulate each other. An increase in the
activity of T helper 2 cells and suppression of T helper
1 cells is likely to be one mechanism of its action.
HBO therapy may also act through the modulation of
the relative concentration of high affinity and low
affinity IL-2 receptors on T lymphocytes. Binding to
the high affinity receptors promotes proliferation
while the reverse is true of the low affinity ones.
HBO may lead to a change in the proportion of
the two receptors leading to reduced T-cell prolifera-
tion [49,50].
HBO therapy has also been shown to alter cell
surface MHC class I antigen expression. The binding
of MHC class I specific antibodies showed reduced
affinity after thyroid and human fetal pancreas allo-
grafts were cultured with exposure to HBO therapy
[5154]. The expression of CD4 was slightly de-
creased when treated by HBO in culture, while that of
CD28, CD80 and CD8 remained unchanged. Altered
peptide ligands interacting with the TCR/CD3 com-
plex may partially activate T cells leading to different
signal transduction pathways [55]. Such altered pep-
tide ligands have the capacity to turn a potentially
harmful T helper 1 response into a protective T helper
2 cell response [56,57]. Recognition of this phenom-
enon and the understanding that such T cells may
then undergo phenotypical changes has led to further
insights into the potential action of HBO therapy. In
addition to the potential direct immunomodulatory
effects, HBO therapy may also significantly affect
ACR by modulating the severity of IPRI. The effects
of HBO therapy on IPRI have been studied in detail in
many clinical and experimental situations.
Mechanisms of action of HBO on IPRI
HBO has been used with beneficial therapeutic effect
in a wide variety of models of IPRI including
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myocardium, skeletal muscle, small intestine and the
liver [58]. Despite the theoretical adverse effects of
generating ROS during reperfusion, the majority of in
vivo studies have shown a reduction in the tissue
injury when reperfusion is performed in the presence
of HBO. HBO interacts with the effects of IPRI at
numerous interfaces, which include the endothelium,
neutrophils, mediators of inflammation, microvascu-
lar blood flow [59], lipid peroxidation and cellular
energy levels.
The earliest demonstrable effect of HBO is on
adhesion of neutrophils within the microcirculation. A
significant reduction in rolling and adhesion on
neutrophils is noted [59]. Recently, Kihara et al.
demonstrated a significant reduction in the accumula-
tion of neutrophils and severity of IPRI in a rat model
when HBO was delivered within 3 h. This resulted in
a significant reduction in neutrophil accumulation,
suppression of malondialdehyde (MDA) within the
affected tissue and reduced congestion within sinu-
soids [60]. Furthermore, HBO therapy resulted in
the specific reduction in the expression of CD11/18
adhesion molecule which acts as a ligand to ICAM-1,
thus leading to the above effect [61]. Neutrophil
adhesion also occurs through the up-regulation of
selectins (P and E selectins) and the immunoglobulin
superfamily (ICAM-1), all of which are expressed on
endothelial surfaces. P-selectin is present in its pre-
made form within cells and therefore up-regulates and
binds very rapidly to its ligand CD15 on the neu-
trophils. E-selectin up-regulation requires new synth-
esis and is thus slower and binds to the sialyl-Lewis
molecule on neutrophils. As previously mentioned,
ICAM-1 molecules bind to CD18 on neutrophils
and are induced by IL-1, TNF-a and bacterial LPS.
In vitro experiments have shown that single doses
of HBO have a significant effect on IPRI-injured
endothelial cells and neutrophil adhesion, by reducing
not only CD18 and CD11expression but also en-
dothelial ICAM-1 expression [62,63]. The latter
effect is thought to act through the induction of
endothelial nitric oxide synthase (eNOS) [64]. This
contradicts other studies which demonstrated in-
creased expression of ICAM-1 with prolonged HBO
therapy. However, the latter studies were conducted
on normal tissue not exposed to the deleterious effects
of IPRI, which may explain the different outcomes.
NO is a free radical which plays a major role in
various aspects of IPRI. It is produced by three types
of NOS. eNOS is constitutively expressed in endothe-
lial cells and plays a role in vasodilatation of the
microcirculation in response to hypoxia. Inducible
NOS (iNOS) is produced by neutrophils and macro-
phages in response to a number of stimuli including
IL-1, TNF-a and bacterial LPS. The NO produced
by iNOS activation results in increased vascular leak
and tissue injury, unlike the beneficial effects of
eNOS. This toxicity is likely to be due to the greater
production of superoxide radicals rather than toxicity
from NO itself. Normobaric oxygen therapy has been
shown to induce eNOS production while HBO
therapy reduces serum nitrite/nitrate concentration
in a rat shock model, where the likely source of nitrate
is from iNOS. A number of in vitro and in vivo studies
have subsequently confirmed the ability of HBO to
selectively induce eNOS while inhibiting iNOS pro-
duction [65].
Lipid peroxidation occurs in the presence of IPRI,
due to the release of ROS leading to cell membrane
and organelle injury. Exposure to normobaric 100%
oxygen increases the degree of such injury during
reperfusion. Although HBO has been noted to in-
crease ROS, a number of studies on IPRI have
confirmed the reduction of lipid peroxidation when
exposed to HBO [66,67]. The underlying mechanism
of this effect remains ill understood. Similarly the
interaction between HBO therapy and cytokine re-
lease remains contradictory. Spontaneous TNF-a
production from normal tissue increases with HBO
therapy in animal studies [68]. However, initial HBO
exposure inhibits TNF-a production following sub-
sequent exposure to bacterial LPS. Other studies have
shown that stimulus-induced synthesis of TNF-a and
IL-1 is inhibited transiently. In an intestinal IPRI
model HBO was shown to inhibit the production of
TNF-a [69]. Prolonged exposure to HBO reverses
this effect leading to an increased production of IL-1
[70]. In other animal studies, once shock had been
induced HBO tended to reduce the production of
TNF-a, suggesting a possible role in the treatment of
IPRI. Yet another mode of its effect may be through
the inhibition of apoptosis. Specific inhibition of the
apoptosis executor caspases 3 and 7 has been shown
to reduce graft injury from IPRI [71]. Studies on
cerebral ischaemia have further confirmed the ability
of HBO to inhibit apoptosis leading to a reduction
in IPRI [72]. Furthermore, a number of in vitro
and in vivo studies have confirmed the ability of
HBO therapy to stimulate hepatocyte regeneration
[66,67,73].
In vivo studies of HBO therapy in
transplantation
Despite extensive studies on the in vitro effects of
HBO therapy on allografts, few studies have been
conducted on its effects in vivo, most of which
concentrate on the effect on ischaemia reperfusion
and amelioration of tissue hypoxia. Several studies on
bone and thyroid allografts have demonstrated accel-
erated union and immunomodulatory effect of HBO
therapy [74]. The main finding was a reduction in the
expression of MHC class I antigen on the allografts
[51,53]. HBO therapy has a number of different
roles in pancreatic islet cell transplantation, as it
also improves the initial allograft hypoxia that is
associated with graft failure. A more detailed study
of islet allograft transplantation was preformed by
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Juang et al., who demonstrated a significant advantage
in using HBO therapy [75]. Better outcome was noted
with pre-transplantation HBO therapy to the donor as
well as twice-daily HBO therapy in the post trans-
plantation period. The use of syngenic animals as
donor and recipient indicates that the graft survival
advantage in this study is related to non-immunolo-
gical mechanisms [75]. Rat fetal spinal transplanta-
tion into adult Wistar rats also demonstrated similar,
non-immunogenic advantages from HBO therapy.
These were due to a combination of reduction in
tissue hypoxia and tissue oedema and an increase in
microvascular proliferation at the graft interface lead-
ing to better graft survival [76].
A rat model of liver transplantation was used by
Chen et al. to demonstrate the effect of a single
episode of pre-transplantation HBO therapy [77].
Post sinusoidal blood flow rate was increased and
leukocyte adherence reduced. Tissue levels of MDA
were reduced while tissue ATP levels were increased
[77]. However, no in vivo studies on liver transplanta-
tion have specifically investigated the immunomodu-
latory effect of HBO therapy.
Another potential role for HBO therapy is its use in
acute liver failure. Liver failure induced by carbon
tetrachloride (CCL4) poisoning in rats was shown to
improve survival from 31% to 96% when applied
immediately after ingestion of the substance. When
applied 24 h later, the survival only improved from
36% to 50% [78]. This effect seems to be specific
against the actions of CCL4 and more study is
required in its application for other causes of acute
liver failure. HBO therapy seems to be protective
against hepatotoxic agents that undergo reductive
biotransformation through the cytochrome P450
system and aggravates the injury caused by those
that undergo oxidative transformation [79].
Clinical experience of HBO therapy in liver
transplantation
A handful of clinical studies have been published on
the use of HBO therapy in relation to liver transplan-
tation. All such studies relate to either its use in the
post transplantation period for the management of
hepatic artery thrombosis (HAT) [80,81] or its use in
acute liver failure prior to transplantation [82,83]. A
single case report of a 3-year-old with fulminant
hepatic failure did not show any advantage to HBO
therapy. The clinical improvement was related to
episodes of plasma exchange. However, HBO therapy
was instituted only on day 18 and as such may have
missed the window of effectiveness [82]. Blum et al.
reported four children with hepatic coma treated by
exchange transfusion of whom three underwent
HBO therapy [84]. Exchange transfusion was noted
to be clinically effective while HBO therapy did not
contribute to an improvement in their neurological
status [84]. HBO therapy was used to treat early post
transplantation HAT in children by Mazariegos et al.
[81]. This study investigated 375 patients who under-
went liver transplantation between 1989 and 1998, of
whom 31 developed HAT (7.5%) at a mean time of
8.2 days. Fourteen patients (between 1989 and 1994)
were treated conventionally and served as the histor-
ical control group. Seventeen patients underwent
HBO therapy within 24 h of HAT between 1994
and 1998. Eight patients in each group underwent re-
transplantation, at a mean time of 12.7 days for the
control group and 157 days for the HBO group. None
of the re-transplantations in the HBO group was due
to hepatic necrosis. There was one death in the HBO
group and five in the control group, although the
latter had a much longer follow-up. Hepatic arterial
collaterals were noted on Doppler ultrasound at a
mean time of 14 days in the HBO group while the
control group demonstrated such development at a
mean time of 31 days. This may in part explain the
lack of hepatic necrosis in the HBO group [81].
HBO therapy in liver transplantation 
discussion
Since its inception in 1662 and practical application in
1930, application of HBO therapy has continued to
elicit controversy [85]. Its use is well established in the
treatment of decompression sickness and generally
accepted for the treatment of carbon monoxide
poisoning, gas embolism and radio-necrosis [86]. Its
remains controversial in the management of chronic
wounds, refractory osteomyelitis, burns, ischaemic
flaps and multiple sclerosis. The fact that HBO
therapy increases the oxygen supply to the target
tissue is unquestioned. This is more so in the liver
with its dual blood supply. In addition, the effect of
HBO therapy in ameliorating IPRI has been investi-
gated to a great depth [87]. However, its potential role
in immunomodulation remains uncertain [37,88].
Liver transplantation and HBO therapy have some
common limitations. Both require extensive financial,
medical and supportive infrastructure to function
adequately. This simple commonality may allow
both specialties to be situated within the same facility
or within easy supportive range, thus providing an
advantage in their clinical application. As the demand
for liver transplantation grows and innovation forces
the clinician to accept grafts of smaller volumes (split-
liver, living-related OLTx) and those with less viable
hepatocytes (marginal donor liver, steatotic livers) it
becomes imperative to develop methods of minimiz-
ing donor organ injury and loss due to the IPRI and
the process of rejection. In particular, the use of
marginal donor organs is associated with an increased
risk of PNF and primary poor function (PPF) of the
graft, leading to longer stays in intensive care units,
morbidity and mortality. PNF is a relative emergency
often requiring urgent re-transplantation. Based on
the available scientific evidence, HBO seems to have
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the capacity to influence the outcomes of liver
transplantation at multiple levels.
The effect of HBO therapy on IPRI is the one that
has been most investigated, defined and applied in
clinical practice, although not in the field of liver
transplantation. HBO therapy seems to reduce the
effect of IPRI by various mechanisms depending on
where it is applied, including exposure to the donor
organ prior to re-implantation as well as the recipient
both before and after transplantation [89,90]. It has
the potential to reduce IPRI and improve graft
function in the post transplantation period. It may
be of particular relevance when marginal or reduced
size donor organs are used. HBO therapy also has a
role to play in the management of post transplantation
complications. Clinical evidence suggests that HBO
therapy may delay or even eliminate hepatic necrosis
following HAT [81]. It has also been used in acute
fulminant hepatic failure [82,84]. In both situations
it may provide badly needed time for an urgent
donor organ to be made available. In the latter
situation it may act as a hepatic assist device in
conjunction with haemofiltration and plasma ex-
change procedures [83].
Another important role for which there is much
animal and in vitro evidence but no clinical studies is
its role in immunomodulation. If the laboratory
studies were proven in the clinical situation, it may
provide the opportunity to minimize drug-based
immunosuppression, particularly in the first week
following transplantation. The effect of minimizing
IPRI is also known to reduce immune activation as it
prevents the up-regulation of MHC class II molecules
in the donor organ [23,91]. The effect of HBO
therapy in ultimately inhibiting the transcription of
immunomodulatory cytokines, especially IL-2 along
with its ability to reduce the expression of MHC class
I antigens, has potential implications for a further,
low dose regime of immunosuppression. Finally, the
proven effect on pancreatic islet cell uptake and graft
survival may allow a similar improvement in the newly
developing technique of hepatocyte transplantation.
Most strategies aimed at minimizing IPRI act
through very specific pathways. This includes the
use of preservation solutions, hepatic microcirculatory
expansion [92], continuous ex vivo hepatic perfusion,
inactivation of Kupffer cells [93] and inhibition of
complement activation [94,95]. Similarly the main-
stay of controlling ACR remains with immunosup-
pressive therapies targeting specific channels such as
inhibition of calcineurin [96], use of antimetabolites
[97] or more recently the use of interleukin receptor
blockade [98]. One of the major and unique potential
advantages of HBO therapy is that it affects the
processes of IPRI and ACR through numerous
cellular and molecular mechanisms. In addition it
may play potential roles as a liver support adjunct for
fulminant hepatic failure, post transplantation graft
dysfunction and acute hepatic artery thrombosis. The
difficulty of moving critically ill patients in and out
of the chambers and the high infrastructure require-
ments have been major obstacles to the delivery of
HBO therapy in the clinical setting. However, the
technology relating to the delivery of HBO therapy
has advanced significantly in the past decades and
overcome most of such impediments. The older
generation of single chamber units were small with
limited space and cumbersome access which in-
creased the difficulty of managing complex patients.
Modern multi-chamber units, especially the rectan-
gular hyperbaric systems, are large by comparison,
with adequate internal space for multiple patients,
active medical intervention and easy drive-in access
for bed-bound critically ill patients and supporting
equipment. Almost all liver transplantation activity
occurs at major referral centres which have the
capacity, staff and infrastructure required for the
functioning of an HBO chamber and the safe delivery
of HBO therapy to critically ill patients. Thus, HBO
therapy, often described as ‘a treatment looking for a
disease’ has the potential to intervene and influence
the outcomes of liver transplantation through multiple
avenues. However, more research is required on the
influence of HBO therapy in liver transplantation,
specifically in its effect on immune response and liver
support prior to clinical applicability.
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